The decision by physicians to make greater use of surgical sealants, glues, hemostats and anti-adhesion products ("securement products") for specific medical/surgical procedures is impacted by cost-effectiveness criteria as well as the substantial clinical benefit they offer. Below are described the four categories of surgical cases, distinguished through the level of clinical need and procedure enabling benefits, as well as the cost-effectiveness dynamics of the products. These categories are useful as predictors for uptake of existing approved adjunctive closure and securement products, as well as new products as they penetrate untapped markets in both the United States and the rest of the world.
Category I: Important and Enabling
Important to prevent excessive bleeding and transfusion, to ensure safe procedure, and to avoid mortality and to avoid complications associated with excessive bleeding and loss of blood.
Category II: Improved Clinical Outcome
Reduces morbidity due to improved procedure, reduced surgery time, and prevention of complications such as fibrosis, post-surgical adhesion formation, and infection (includes adjunct to minimally invasive surgery).
Category III: Cost-Effective and Time-Saving
Immediate reduction in surgical treatment time and follow-up treatments.
Category IV: Aesthetic and Perceived Benefits
Selection is driven by aesthetic and perceived benefits, resulting in one product being favored over a number of medically equivalent treatments.
Considering the categories above, we forecast relative procedure volume uptake by surgeons using securement products with varying rates driven by the benefits the products provide within different clinical specialties.
Source: MedMarket Diligence’s Report #S175, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2009-2013."